Kewalramani Reshma — SEC Form 4 filings
SEC reporting owner CIK 1735944. 23 Form 4 filings on record with FilingPulse; latest filed 2026-03-03.
Transaction summary — filings shown
Covers all 23 filings on record, filed 2024-02-08 to 2026-03-03. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 2 legs across 1 filing — 10,000 shares, $3,895,768 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 18 legs across 6 filings — 102,369 shares, $50,308,728 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 25.
- Largest priced transaction: sale of 15,198 shares @ $515.00 ($7,826,970) in VERTEX PHARMACEUTICALS INC / MA, filed 2024-11-12.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | CEO & President, Director | 22 | 2 legs · 10,000 sh · $3,895,768 | 18 legs · 102,369 sh · $50,308,728 | 23 |
| Ginkgo Bioworks Holdings, Inc. (DNA) | Director | 1 | — | — | 2 |
Form 4 filings — Kewalramani Reshma
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-03-03 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Sale (S): 400 @ $479.75 · Sale (S): 120 @ $481.50 · Sale (S): 240 @ $482.84 · Sale (S): 2,510 @ $487.13 · Sale (S): 3,278 @ $488.27 · Sale (S): 460 @ $489.32 · +7 more | EDGAR |
| 2026-02-26 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Tax withholding (F): 4,981 @ $485.11 | EDGAR |
| 2026-02-19 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Grant/award (A): 16,326 @ $0 · Tax withholding (F): 6,554 @ $483.75 | EDGAR |
| 2026-02-18 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Tax withholding (F): 13,041 @ $487.76 | EDGAR |
| 2026-02-12 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Tax withholding (F): 8,297 @ $468.41 | EDGAR |
| 2026-01-26 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Grant/award (A): 26,972 @ $0 · Grant/award (A): 11,885 @ $0 | EDGAR |
| 2025-08-07 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Purchase (P): 4,290 @ $389.08 · Purchase (P): 5,710 @ $389.95 | EDGAR |
| 2025-02-28 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Tax withholding (F): 14,079 @ $479.61 | EDGAR |
| 2025-02-26 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Tax withholding (F): 9,386 @ $483.28 | EDGAR |
| 2025-02-19 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Tax withholding (F): 6,553 @ $463.46 | EDGAR |
| 2025-02-14 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Grant/award (A): 19,015 @ $0 | EDGAR |
| 2025-02-12 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Tax withholding (F): 8,300 @ $467.98 | EDGAR |
| 2025-02-06 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Grant/award (A): 29,118 @ $0 · Grant/award (A): 20,328 @ $0 | EDGAR |
| 2024-11-12 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Sale (S): 15,198 @ $515 | EDGAR |
| 2024-08-01 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Sale (S): 15,202 @ $505 | EDGAR |
| 2024-07-24 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Sale (S): 15,202 @ $497 | EDGAR |
| 2024-06-14 | 4 | Ginkgo Bioworks Holdings, Inc. (DNA) | Option exercise (M): 105,263 · Option exercise (M): 105,263 (derivative) | EDGAR |
| 2024-05-29 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Option exercise (M): 1,565 @ $187.53 · Sale (S): 1,565 @ $457 · Option exercise (M): 1,565 (derivative) @ $0 | EDGAR |
| 2024-05-22 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Sale (S): 15,202 @ $447 | EDGAR |
| 2024-02-27 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Tax withholding (F): 9,386 @ $431.79 | EDGAR |
| 2024-02-21 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Tax withholding (F): 9,359 @ $424.01 · Tax withholding (F): 7,019 @ $420.58 | EDGAR |
| 2024-02-13 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Tax withholding (F): 8,255 @ $422.74 | EDGAR |
| 2024-02-08 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Grant/award (A): 14,516 @ $0 · Grant/award (A): 26,972 @ $0 · Grant/award (A): 20,327 @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1735944 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →